Respiratory medicine
Clinical research includes maintenance bronchodilator treatment for adults with chronic obstructive pulmonary disease (COPD), with interest in inhaled therapies used to ease persistent respiratory symptoms.
- Chronic obstructive pulmonary disease
- Maintenance bronchodilation
- Inhaled combination therapy
The respiratory portfolio reflects a focus on treatments intended to support ongoing symptom control in long-term obstructive airway disease.
Cardiovascular disease
The sponsor is active in studies related to atherothrombotic prevention for adults with acute coronary syndromes (ACS) and for patients with a history of myocardial infarction (MI) at elevated risk of recurrent events.
- Acute coronary syndromes
- Myocardial infarction
- Atherothrombotic event prevention
Work in this area centres on antithrombotic therapies relevant to secondary prevention in high-risk cardiovascular populations.
Stroke prevention and atrial fibrillation
Research activity also covers prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) and additional risk factors such as prior transient ischaemic attack (TIA), advanced age, hypertension, diabetes mellitus, and symptomatic heart failure.
- Non-valvular atrial fibrillation
- Stroke prevention
- Systemic embolism
This area links anticoagulant development with prevention of thromboembolic complications in patients with cardiac rhythm disorders.
Venous thromboembolism
Additional trials address treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), together with prevention of recurrent venous thromboembolic events in adults.
- Deep vein thrombosis
- Pulmonary embolism
- Recurrent venous thromboembolism
The therapeutic emphasis in this field is on anticoagulant management for acute and secondary prevention of venous clotting disorders.
